Fajgenbaum, David C <br/><br/>
Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.  [electronic resource] 

 -  Immunotherapy  2016 
 - 17-26 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1750-7448 
<br/><br/><label>Standard No.: </label>10.2217/imt.15.95  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Biomarkers<br/>Castleman Disease--immunology<br/>Humans<br/>Immunotherapy<br/>Interleukin-6--immunology